Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that ...

For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Nano-X Imaging Ltd. (NNOX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Nano-X Imaging Ltd. is a member of the Business Services sector. This group includes 316 individual stocks and currently ho ...

Nvidia is holding the stock, but that doesn't necessarily make it a terrific investment for everyday investors. Shares of Nano-X Imaging (NNOX -1.18%) are down about 53% over the past 12 months, and it's not hard to understand why. The company generated a lot of buzz when it earned Food and Drug Administration (FDA) clearance to market the Nanox.ARC a little over a year ago, but sales haven't grown. The Nanox.ARC employs proprietary technology that produces X-rays with far less electricity, which should red ...

Nano-X Imaging Ltd. (NASDAQ:NNOX) Q1 2024 Earnings Conference Call May 28, 2024 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Erez Meltzer - Chief Executive Officer Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeff Cohen - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Nanox First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's pres ...

Accelerates Deployment of Nanox.ARC in United States Signed two commercial agreements for Nanox.AI Management to host conference call and webcast Tuesday, May 28, 2024 at 8:30 AM ET PETAH TIKVA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2024 and provided a business update. First Quarter 2024 Highlights and Recent Developments: Generated ...

PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parti ...

PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parti ...

Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission's Gold Seal of Approval® for Ambulatory Health Care Accreditation for the sixth time by demonstrating continuous compl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $10.2 million for Q4 2023, a significant decrease from a net loss of $52.8 million in Q4 2022, primarily due to a goodwill impairment and a decrease in general and administrative expenses [29][30]. - Revenue for Q4 2023 was $2.4 million, compared to $2.1 million in the same period last year, with a gross loss of $1.7 million on a GAAP basis [30][31]. - Non-GAAP gross profit for the reported period was $0.9 million, representing a gross profit margin of approximately 36%, down from 39% in the comparable period [30][31]. Business Line Data and Key Metrics Changes - The company generated $84,000 in revenue from AI solutions in Q4 2023, an increase from $63,000 in the previous period [32]. - Revenue from teleradiology services was $2.3 million with a gross profit of $0.3 million, compared to $2.1 million and $0.3 million in the prior year [88]. Market Data and Key Metrics Changes - The company has expanded its U.S. deployment of the Nanox.ARC system across five states, with installations in New Jersey, New York, Florida, Kansas, and Georgia [9][12]. - In Africa, the company has three installations, including one at the University of Ghana Medical Center, and has signed a multisite agreement for a clinical trial [13]. Company Strategy and Development Direction - The company aims to accelerate the commercialization of the Nanox.ARC system and expand its U.S. sales and technical teams [8][12]. - The strategy includes a focus on the MSaaS model for revenue generation, with initial deployments validating this approach [10][12]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2024 being a transformative year for the company, with expectations for increased deployment and revenue generation from the Nanox.ARC system [7][8]. - The company is also pursuing CE Mark designation in the EU and has received local regulatory clearances in countries like Ghana [43][28]. Other Important Information - The company achieved FDA clearance for the Nanox.ARC system, marking a significant milestone in its U.S. commercialization efforts [7][19]. - The company has made progress in its AI solutions, with a 250% increase in its client base compared to the previous quarter [17]. Q&A Session Summary Question: How many systems in the U.S. are operational across the five states deployed in during the fourth quarter? - The company has systems installed in five states but has not disclosed the exact number of operational systems yet [48][49]. Question: What types of centers are adopting ARC, and how is utilization trending? - The company reported that small and medium-sized medical imaging centers are adopting ARC, with some centers achieving up to 15 scans per day [52][76]. Question: Can you provide details on the economics of Connect in Peru and Mexico? - Most agreements for Connect are based on the MSaaS model, with some capital sales depending on the country [53][54]. Question: How do you see the utilization of Nanox.ARC scaling in 2024? - The company anticipates that utilization will increase, with early installations averaging seven scans per day, and some centers achieving higher numbers [75][76]. Question: What is the expected volume of patients analyzed with HealthCCS at Intermountain? - The company noted that 60% of patients in studies were previously undetected with cardiovascular risks, indicating significant potential for future analysis [80][82].